Form 4: Xeris Biopharma Director Awarded 50,000 Restricted Stock Units, Boosting Beneficial Ownership

Xeris Biopharma Holdings, Inc. director Barbara-Jean Anne Bormann-Kennedy was granted 50,000 restricted stock units, increasing her beneficial ownership to 157,500 shares.

Summary

• Barbara-Jean Anne Bormann-Kennedy, a Director of Xeris Biopharma Holdings, Inc. (XERS), was awarded 50,000 shares of common stock on June 4, 2025.
• These shares were granted as Restricted Stock Units (RSUs) under the Company's 2018 Stock Option and Incentive Plan, with each RSU representing a contingent right to receive one share of common stock.
• The acquisition price for these shares was $0, indicating an award rather than a purchase.
• Following this transaction, Ms. Bormann-Kennedy's direct beneficial ownership in the company increased to a total of 157,500 shares.
• The awarded RSUs are scheduled to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The filing reports a standard RSU award to a director, which is a positive for aligning interests and retention, but it's a routine event and not indicative of significant new positive or negative company performance.

Positives

• The award of Restricted Stock Units (RSUs) to a director aligns management's interests with those of shareholders, incentivizing long-term performance and retention.
• The grant is part of the company's established 2018 Stock Option and Incentive Plan, indicating a structured and routine approach to executive compensation.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it reports a standard compensation event.

Future Outlook

The 50,000 Restricted Stock Units granted to Director Barbara-Jean Anne Bormann-Kennedy are scheduled to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.

Industry Context

This transaction represents a routine compensation event for a director in the biopharmaceutical industry, utilizing Restricted Stock Units (RSUs) as a common incentive mechanism to align executive interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The RSU award aligns the director's interests with shareholders by incentivizing long-term stock performance. It also represents potential future dilution upon vesting, though this is typically factored into compensation plans.

Next Steps

• The 50,000 Restricted Stock Units are expected to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Xeris Biopharma Holdings Inc, XERS, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Stock Award, Insider Ownership, Biopharma, Pharmaceuticals